Abstract

The treatment of chronic myeloproliferative neoplasms, including chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia are summarized. The indications for supportive care versus chemotherapy versus targeted (kinase inhibitor) therapy and stem cell transplantation are compared.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call